Cost recovery implementation statement
Version 1.1 June 2017
4 July 2017
Appendix 1 - Financial performance by industry sector group
1. Prescription medicines
| Volumes[4] | 2015-16 Actual |
2016-17 Forecast |
2017-18 Budget |
2018-19 Estimate |
2019-20 Estimate |
|---|---|---|---|---|---|
| Biological prescription medicines | 580 | 486 | 486 | 486 | 486 |
| Non-biological prescription medicines - higher charge | 522 | 493 | 493 | 493 | 493 |
| Non-biological prescription medicines - lower charge | 6,536 | 5,640 | 5,640 | 5,640 | 5,640 |
| Revenue and expenses | 2015-16 Actual $'m |
2016-17 Forecast $'m |
2017-18 Budget $'m |
2018-19 Estimate $'m |
2019-20 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Cost recovery revenue | 71.7 | 69.6 | 71.2 | 73.2 | 74.3 |
| Total A | 71.7 | 69.6 | 71.2 | 73.2 | 74.3 |
| B: Expenses | |||||
| Direct | 36.9 | 39.7 | 41.8 | 43.1 | 43.7 |
| Indirect | 26.3 | 28.3 | 29.8 | 30.7 | 31.2 |
| Total B | 63.2 | 68.0 | 71.6 | 73.8 | 74.9 |
| Surplus (deficit) | 8.5 | 1.6 | (0.4) | (0.6) | (0.6) |
2. Over the counter medicines
| Volumes[6] | 2015-16 Actual |
2016-17 Forecast |
2017-18 Budget |
2018-19 Estimate |
2019-20 Estimate |
|---|---|---|---|---|---|
| Over the counter medicines | 2,667 | 2,417 | 2,417 | 2,417 | 2,417 |
| Revenue and expenses | 2015-16 Actual $'m |
2016-17 Forecast $'m |
2017-18 Budget $'m |
2018-19 Estimate $'m |
2019-20 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Cost recovery revenue | 6.7 | 7.7 | 7.9 | 8.1 | 8.3 |
| Total A | 6.7 | 7.7 | 7.9 | 8.1 | 8.3 |
| B: Expenses[7] | |||||
| Direct | 2.8 | 3.4 | 3.1 | 3.2 | 3.3 |
| Indirect | 2.3 | 2.9 | 2.6 | 2.7 | 2.8 |
| Total B | 5.1 | 6.2 | 5.8 | 6.0 | 6.1 |
| Surplus (deficit) | 1.6 | 1.5 | 2.1 | 2.2 | 2.2 |
3. Complementary medicines
| Volumes[8] | 2015-16 Actual |
2016-17 Forecast |
2017-18 Budget |
2018-19 Estimate |
2019-20 Estimate |
|---|---|---|---|---|---|
| Registered complementary medicines | 132 | 133 | 133 | 133 | 133 |
| Listed complementary medicines | 11,003 | 10,238 | 10,238 | 10,238 | 10,238 |
| Revenue and expenses | 2015-16 Actual $'m |
2016-17 Forecast $'m |
2017-18 Budget $'m |
2018-19 Estimate $'m |
2019-20 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Cost recovery revenue | 15.7 | 14.0 | 14.3 | 14.7 | 14.9 |
| Total A | 15.7 | 14.0 | 14.3 | 14.7 | 14.9 |
| B: Expenses[9] | |||||
| Direct | 7.2 | 7.8 | 8.1 | 8.4 | 8.5 |
| Indirect | 5.2 | 5.7 | 5.9 | 6.1 | 6.2 |
| Total B | 12.4 | 13.5 | 14.0 | 14.5 | 14.7 |
| Surplus (deficit) | 3.3 | 0.5 | 0.3 | 0.2 | 0.3 |
4. Medical devices, including in-vitro diagnostic (IVD) devices
| Volumes[10] | 2015-16 Actual |
2016-17 Forecast |
2017-18 Budget |
2018-19 Estimate |
2019-20 Estimate |
|---|---|---|---|---|---|
| Included medical devices | 44,878 | 45,471 | 45,471 | 45,471 | 45,471 |
| IVD medical devices | N/A | N/A | 2,492 | 2,492 | 2,492 |
| Other therapeutic goods | 359 | 279 | 279 | 279 | 279 |
| Revenue and expenses | 2015-16 Actual $'m |
2016-17 Forecast $'m |
2017-18 Budget $'m |
2018-19 Estimate $'m |
2019-20 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Cost recovery revenue | 34.3 | 36.0 | 36.8 | 37.8 | 38.4 |
| Total A | 34.3 | 36.0 | 36.8 | 37.8 | 38.4 |
| B: Expenses[11] | |||||
| Direct | 17.1 | 19.3 | 19.4 | 20.0 | 20.3 |
| Indirect | 12.2 | 13.7 | 13.8 | 14.3 | 14.5 |
| Total B | 29.4 | 33.0 | 33.3 | 34.3 | 34.8 |
| Surplus (deficit) | 4.9 | 3.0 | 3.5 | 3.5 | 3.6 |
5. Good manufacturing practices
| Volumes[12] | 2015-16 Actual |
2016-17 Forecast |
2017-18 Budget |
2018-19 Estimate |
2019-20 Estimate |
|---|---|---|---|---|---|
| Low level GMP licence | 105 | 111 | 111 | 111 | 111 |
| High level GMP licence | 163 | 161 | 161 | 161 | 161 |
| Revenue and expenses | 2015-16 Actual $'m |
2016-17 Forecast $'m |
2017-18 Budget $'m |
2018-19 Estimate $'m |
2019-20 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Cost recovery revenue | 11.2 | 10.3 | 10.5 | 10.8 | 11.0 |
| Total A | 11.2 | 10.3 | 10.5 | 10.8 | 11.0 |
| B: Expenses[13] | |||||
| Direct | 7.8 | 9.2 | 8.8 | 9.1 | 9.2 |
| Indirect | 5.4 | 6.4 | 6.1 | 6.3 | 6.4 |
| Total B | 13.2 | 15.6 | 14.9 | 15.4 | 15.6 |
| Surplus (deficit) | (2.0) | (5.3) | (4.4) | (4.6) | (4.6) |
6. Blood, blood components and biologicals
| Volumes[14] | 2015-16 Actual |
2016-17 Forecast |
2017-18 Budget |
2018-19 Estimate |
2019-20 Estimate |
|---|---|---|---|---|---|
| Blood primary site | 5 | 5 | 5 | 5 | 5 |
| Blood secondary site | 79 | 75 | 75 | 75 | 75 |
| Single step manufacturer of human tissue | 24 | 17 | 17 | 17 | 17 |
| Class 2 biological products | 20 | 19 | 19 | 19 | 19 |
| Class 3 biological products | 5 | 6 | 6 | 6 | 6 |
| Revenue and expenses | 2015-16 Actual $'m |
2016-17 Forecast $'m |
2017-18 Budget $'m |
2018-19 Estimate $'m |
2019-20 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Cost recovery revenue | 2.2 | 2.4 | 2.5 | 2.6 | 2.6 |
| Total A | 2.2 | 2.4 | 2.5 | 2.6 | 2.6 |
| B: Expenses[15] | |||||
| Direct | 1.6 | 1.5 | 1.8 | 1.9 | 1.9 |
| Indirect | 1.3 | 1.2 | 1.4 | 1.5 | 1.5 |
| Total B | 2.9 | 2.6 | 3.2 | 3.3 | 3.4 |
| Surplus (deficit) | (0.6) | (0.2) | (0.7) | (0.8) | (0.8) |
7. Other activities
| Revenue and expenses | 2015-16 Actual $'m |
2016-17 Forecast $'m |
2017-18 Budget $'m |
2018-19 Estimate $'m |
2019-20 Estimate $'m |
|---|---|---|---|---|---|
| A: Revenue | |||||
| Revenue | 2.0 | 1.6 | 1.7 | 1.7 | 1.7 |
| Total A | 2.0 | 1.6 | 1.7 | 1.7 | 1.7 |
| B: Expenses | |||||
| Other Expense | 2.0 | 2.7 | 2.0 | 1.7 | 1.7 |
| MMDR Expense | N/A | 6.9 | 3.6 | N/A | N/A |
| Total B | 2.0 | 9.6 | 5.6 | 1.7 | 1.7 |
| Surplus (deficit) | 0.0 | (8.0) | (4.0) | 0.0 | 0.0 |
Footnotes
- Number of entries on the ARTG subject to the annual charge.
- Following the internal organisation restructure (industry sector based) within the TGA, a new activity based costing model has been developed in 2016-17 based on a staff effort survey undertaken in 2016-17. The allocation of direct and indirect expenses is based on the ratio from the most recent 2016-17 model. The TGA will continue to review the costing model and apply changes when necessary.
- Number of entries on the ARTG subject to the annual charge.
- Following the internal organisation restructure (industry sector based) within the TGA, a new activity based costing model has been developed in 2016-17 based on a staff effort survey undertaken in 2016-17. The allocation of direct and indirect expenses is based on the ratio from the most recent 2016-17 model. The TGA will continue to review the costing model and apply changes when necessary.
- Number of entries on the ARTG subject to the annual charge.
- Following the internal organisation restructure (industry sector based) within the TGA, a new activity based costing model has been developed in 2016-17 based on a staff effort survey undertaken in 2016-17. The allocation of direct and indirect expenses is based on the ratio from the most recent 2016-17 model. The TGA will continue to review the costing model and apply changes when necessary.
- Number of entries on the ARTG subject to the annual charge.
- Following the internal organisation restructure (industry sector based) within the TGA, a new activity based costing model has been developed in 2016-17 based on a staff effort survey undertaken in 2016-17. The allocation of direct and indirect expenses is based on the ratio from the most recent 2016-17 model. The TGA will continue to review the costing model and apply changes when necessary.
- Number of entries on the ARTG subject to the annual charge.
- Following the internal organisation restructure (industry sector based) within the TGA, a new activity based costing model has been developed in 2016-17 based on a staff effort survey undertaken in 2016-17. The allocation of direct and indirect expenses is based on the ratio from the most recent 2016-17 model. The TGA will continue to review the costing model and apply changes when necessary.
- Number of entries on the ARTG subject to the annual charge.
- Following the internal organisation restructure (industry sector based) within the TGA, a new activity based costing model has been developed in 2016-17 based on a staff effort survey undertaken in 2016-17. The allocation of direct and indirect expenses is based on the ratio from the most recent 2016-17 model. The TGA will continue to review the costing model and apply changes when necessary.